GLP-1 drugs on every 2026 Delaware Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Delaware cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | Humana Basic Rx Plan$0.00/moS5884-103 | Humana Value Rx Plan$4.30/moS5884-184 | Wellcare Value Script$5.60/moS4802-140 | Wellcare Classic$5.70/moS4802-079 | HealthSpring Assurance Rx$32.60/moS5617-214 | AARP Medicare Rx Saver from UHC$37.80/moS5921-350 | HealthSpring Extra Rx$66.60/moS5617-355 | AARP Medicare Rx Preferred from UHC$94.50/moS5921-387 | SilverScript Choice$97.40/moS5601-010 | Humana Premier Rx Plan$108.60/moS5884-151 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ozempicsemaglutide injection | Tier 3PA25%QL 3/28d | Tier 3PA20%QL 3/28d | Tier 6PA$11.00QL 3/28d | Tier 3PA25%QL 3/28d | Tier 3PA22%QL 3/28d | Tier 3PA17%QL 3/28d | Tier 3PA17%QL 3/28d | Tier 3PA17%QL 3/28d | Tier 5PA25%QL 3/28d | Tier 3PA$45.00QL 3/28d |
| Mounjarotirzepatide injection | Tier 3PA25%QL 2/28d | Tier 3PA20%QL 2/28d | Tier 6PA$11.00QL 2/28d | Tier 3PA25%QL 2/28d | Tier 3PA22%QL 2/28d | Tier 3PA17%QL 2/28d | Tier 3PA17%QL 2/28d | Tier 3PA17%QL 2/28d | Tier 5PA25%QL 2/28d | Tier 3PA$45.00QL 2/28d |
| Trulicitydulaglutide injection | Not covered | Not covered | Tier 6PA$11.00QL 2/28d | Tier 3PA25%QL 2/28d | Tier 3PA22%QL 2/28d | Tier 3PA17%QL 2/28d | Tier 3PA17%QL 2/28d | Tier 3PA17%QL 2/28d | Tier 5PA25%QL 2/28d | Not covered |
| Ozempic tabletsoral semaglutide, formerly Rybelsus | Not covered | Not covered | Tier 6PA$11.00QL 30/30d | Tier 3PA25%QL 30/30d | Tier 3PA22%QL 30/30d | Tier 3PA17%QL 30/30d | Tier 3PA17%QL 30/30d | Tier 3PA17%QL 30/30d | Tier 5PA25%QL 30/30d | Not covered |
| Wegovysemaglutide, weight | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Zepboundtirzepatide, weight | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Victozaliraglutide | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| liraglutidegeneric Victoza | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Saxendaliraglutide, weight | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | |||||||||
| Byettaexenatide | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | |||||||||
| Bydureon BCiseexenatide extended-release | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | |||||||||
| orforglipronoral GLP-1, approved 2026 | No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are). | |||||||||
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.